Miscarriage, Intrauterine Fetal Demise, Recurrent Pregnancy Loss
Unlocking valuable information and providing clarity for clinicians and patients.

Why Consider Microarray Analysis for Miscarriages?

Over half of all first trimester pregnancy losses are due to chromosomal abnormalities. Unlike older microarray methodologies, the CombiSNP™ has several advantages.

CombiMatrix's microarray testing:

  • Allows for appropriate patient management and recurrence risk counseling
  • Helps prevent unnecessary parental testing
  • Utilizes superior SNP microarray technology
  • Simultaneously detects maternal cell contamination (no additional studies are required)
  • Readily detects triploid and molar pregnancies

Microarray vs. Traditional Chromosomal Analysis

Microarray testing has superior diagnostic power and is better suited to the analysis of miscarriage tissue:




Percentage of cases in which results are obtained

~ 95%

45-85% *

Cell culture required

No (DNA based)

Yes (Frequent cell culture failure)

Can be performed on FFPE tissue



Detects submicroscopic gains and losses



Detects sub-microscopic imbalances and molar pregnancy



Detects Maternal Cell Contamination (MCC)




10-12 days

≥ 3 weeks (if culture is successful)


Finding Answers for Couples With an Intrauterine Fetal Demise (IUFD) or Stillbirth

Chromosomal abnormalities are an important contributor to fetal death, particularly when fetal anatomic abnormalities are present. ACOG’s Committee Opinion No. 581 states: “In cases of intrauterine fetal demise or stillbirth when further cytogenetic analysis is desired, chromosomal microarray analysis on fetal tissue (i.e., amniotic fluid, placenta, or products of conception) is recommended because of its increased likelihood of obtaining results and improved detection of causative abnormalities.”

1st Trimester Losses (no visible fetal parts)

  • Fetal villi from fresh tissue
  • Fetal villi from formalin-fixed, paraffin-embedded (FFPE) samples (Both unstained slides or tissue blocks)

2nd and 3rd Trimester IUFD and Stillbirth

  • Skeletal muscle is the optimal tissue choice
  • Umbilical cord, cord blood and placenta are an excellent options if the family wishes to leave the fetus untouched.

Genetic testing can provide your patients with important information regarding the cause of the loss, as well as recurrence risks for future pregnancies.

Please click below to play the video on the importance of performing Pregnancy Loss Analysis and CombiMatrix's unique approach:

Miscarriage/Recurrent Pregnancy Loss Literature:

Miscarriage Analysis/IUFD with SNP microarray 
Specimen Guide - Pregnancy Loss Analaysis 
Patient brochure - Pregnancy Loss
Patient brochure - Pregnancy Loss - Spanish

To learn more about our Pregnancy Loss Test or to order a kit, simply connect with our Client Services Team at 949.255.0920 or email info@combimatrix.com

Request more information »

* References: Levy B. et al. Genomic Imbalance in Products of Conception, Single-Polymorphism Chromosomal Microarray Analysis. Obstet Gynecol 2014;124:202–9; Wang BT, Sahoo T. et al. Abnormalities in spontaneous abortions detected by G-banding and chromosomal microarray analysis (CMA) at national reference laboratory. Molecular Cytogenetics 2014, 7:33; Reddy UM, et al. Karyotype versus microarray testing for genetic abnormalities after stillbirth. NEJM. 2012; 367:2185-93;  Gao J, et al. Array-based comparative genomic hybridization is more informative than conventional karyotyping and fluorescence in situ hybridization in the analysis of first-trimester spontaneous abortion. MolCytogenet. 2012; 5:33.; Robberecht C, et al. Diagnosis of miscarriages by molecular karyotyping: benefits and pitfalls. Genet Med. 2009; 11(9):646-54; Junger EL, et al. Chromosomal anomalies in first-trimester miscarriages. Acta Obstet Gynecol Scand. 2005; 84:1103-07.